The RBM38 antibody is a research tool designed to detect RNA-binding motif protein 38 (RBM38), a member of the RNA-binding protein family involved in post-transcriptional regulation of gene expression. RBM38. also known as RNPC1. plays critical roles in RNA metabolism, including mRNA splicing, stability, and translation. It interacts with specific RNA targets to modulate processes like cell cycle progression, apoptosis, and differentiation. Notably, RBM38 regulates tumor suppressor p53 by stabilizing its mRNA, influencing cellular stress responses and tumorigenesis.
The RBM38 antibody is widely used in immunoblotting (Western blot), immunohistochemistry (IHC), and immunoprecipitation (IP) to study RBM38 expression, localization, and interactions in various biological contexts. It is particularly valuable in cancer research, as RBM38 exhibits dual roles in tumor progression—acting as a tumor suppressor in some cancers (e.g., breast, colorectal) while promoting aggressiveness in others (e.g., liver, gastric). Studies also explore its involvement in muscle differentiation and hematopoiesis.
Commercial RBM38 antibodies are typically developed in rabbits or mice, validated for specificity against human, mouse, or rat samples. Researchers rely on these antibodies to elucidate RBM38's regulatory mechanisms, its crosstalk with signaling pathways (e.g., p53-MDM2 axis), and potential therapeutic applications. Proper validation via knockout controls or siRNA knockdown is essential to ensure antibody reliability in experimental settings.